AVT04:一种乌斯特基努马布生物类似剂

相关实验视频

Updated: Jun 22, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Hannah A Blair¹

¹Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.

Clinical drug investigation

|July 4, 2024

概括

AVT04 (Uzpruvo®) 是一种与ustekinumab生物相似的药物,在斑块性牛皮患者中表现出类似的疗效和安全性. 切换到AVT04没有显示任何负面影响,提供了可比的治疗选择.

科学领域:

免疫学免疫学免疫学
药理学药理学是指药理学的学科.
生物技术是生物技术.

背景情况:

乌斯特基努马布是一种生物疗法,向介素-12和-23细胞因子.
它被批准用于各种炎症状况,包括斑块性牛皮,牛皮关节炎和克罗恩病.
生物类似药有可能增加患者获得有效的生物治疗的机会.

研究的目的:

为了评估AVT04 (Uzpruvo®),一个生物类似的ustekinumab.
为了比较AVT04的物理化学,药理动力学和临床概况与参考ustekinumab.
评估AVT04的安全性,耐受性和免疫性,包括从参考产品切换.

主要方法:

关于AVT04的物理化学特征和参考 ustekinumab.
在健康志愿者和斑块牛皮患者中进行的药理动力学研究.
临床试验评估中度至重度慢性斑块牛皮患者的疗效,安全性,耐受性和免疫性.
从参考乌斯特基努马布切换到AVT04的评估.

主要成果:

AVT04的物理化学特性与ustekinumab相似.
在相关人群中证明了药理动力学相似性.
临床研究显示AVT04和ustekinumab之间具有可比的疗效,安全性,耐受性和免疫性概况.
从ustekinumab切换到AVT04并没有影响疗效,安全性或免疫性.

结论:

AVT04是一种安全有效的生物相似药物 ustekinumab.
它为患有斑块性牛皮,牛皮性关节炎和克罗恩病的患者提供了可比的治疗选择.
AVT04扩大了通过ustekinumab管理的炎症性疾病的治疗选择.

更多相关视频

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Bioequivalence: Overview

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...